---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-035381"
form_type: "8-K"
ticker: null
cik: "0001801777"
company_name: "Applied Molecular Transport Inc."
filed_at: "2023-12-27T23:59:59+00:00"
generated_at: "2026-06-07T06:58:32.276440+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Applied Molecular Transport completes merger with Cyclo Therapeutics; AMTI becomes wholly owned subsidiary

## Summary
- Each AMTI share converted into 0.1331 shares of Cyclo common stock at merger effective December 27, 2023.
- AMTI requested Nasdaq to suspend trading and delist AMTI common stock; will file Form 15 to deregister.
- All AMTI directors and officers ceased; former AMTI director Shawn Cross appointed to Cyclo board.
- AMTI's charter and bylaws amended and restated per the Merger Agreement.

## SEC filing metadata
- accession: 0001437749-23-035381
- form_type: 8-K
- cik: 0001801777
- company_name: Applied Molecular Transport Inc.
- filed_at: 2023-12-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/amti20231222_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-035381
- JSON: https://secwatch.observer/filing/0001437749-23-035381.json
- Plain text: https://secwatch.observer/filing/0001437749-23-035381.txt

## Key facts
- Executive change
  Shawn Cross was appointed as director at Applied Molecular Transport Inc..
  - Action: appointed
  - Role: director
  source text: Shawn Cross, a former director of AMTI, was appointed to the board of directors of Cyclo.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm
- M&A Transactions
  Applied Molecular Transport Inc. underwent a change of control involving Cyclo Therapeutics, Inc. (closed 2023-12-27).
  - Action: change of control
  - Counterparty: Cyclo Therapeutics, Inc.
  - Closing: 2023-12-27
  source text: On December 27, 2023, Applied Molecular Transport Inc., a Delaware corporation ("AMTI"), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc., a Nevada corporation ("Cyclo"), Cameo Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Cyclo ("Merger Sub") and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.